Company intelligence / Profile preview
Nanopharmaceutics, Inc.
- Ownership
- Private
- Development stage
- Other
Overview
Nanopharmaceutics is a clinical-stage specialty pharmaceutical company leveraging proprietary nanoparticle technologies to develop oral, topical, and injectable therapies for cancer, CNS disorders, diabetes, and infectious diseases. The company has advanced its lead candidate into a Phase 3 trial for cervical/vaginal cancer using triapine plus cisplatin chemoradiation. It also collaborates with PrecisionLife to optimize patient selection in CNS trials using genetic biomarkers.[1][3][5][6]
- Therapeutic areas
- OncologyEndocrinologyNeurologyInfectious Diseases
- Modalities
- Small molecules (notably nanoparticle and fine-particle formulations)[1][5]Oral, topical, and injectable drug products[1][3]
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Nanopharmaceutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanopharmaceutics, Inc..